Invesaro

Stocks Health care AMGN

NASDAQ · Health care

Amgen Inc (AMGN)

Amgen Inc brought in $38.1B of revenue over the twelve months to June 30, 2026, up 9.1% from a year earlier. Net income was $8.7B, a net margin of 23.0%. Operating cash flow minus capital spending left $8.1B of free cash flow in fiscal 2025. At June 30, 2026 it held $14B in cash against $57.3B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.

Price
$414.61
+2.11% on the day · September 25, 2026
52-week range $269.77 to $447.03
Market cap
$224.2B
Revenue (last 12 months)
$38.1B
+9.1% year on year
Net margin
23.0%
P/E
29.1
on FY2025 diluted EPS

What Amgen Inc does

Amgen discovers, develops, and manufactures biologic medicines based on recombinant DNA technology. It produces prescription drugs treating cancer, kidney disease, rheumatoid arthritis, and bone conditions, which it sells to hospitals, clinics, and pharmacies. Its shares trade on NASDAQ under the ticker AMGN.

Revenue and profit by year

Revenue
FY18: $23.7B $23.7B FY18FY19: $23.4B $23.4B FY19FY20: $25.4B $25.4B FY20FY21: $26B $26B FY21FY22: $26.3B $26.3B FY22FY23: $28.2B $28.2B FY23FY24: $33.4B $33.4B FY24FY25: $36.8B $36.8B FY25
Net income
FY18: $8.4B $8.4B FY18FY19: $7.8B $7.8B FY19FY20: $7.3B $7.3B FY20FY21: $5.9B $5.9B FY21FY22: $6.6B $6.6B FY22FY23: $6.7B $6.7B FY23FY24: $4.1B $4.1B FY24FY25: $7.7B $7.7B FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$36.8B$9.1B$7.7B$14.23$8.1B
2024$33.4B$7.3B$4.1B$7.56$10.4B
2023$28.2B$7.9B$6.7B$12.49$7.4B
2022$26.3B$9.6B$6.6B$12.11$8.8B
2021$26B$7.6B$5.9B$10.28$8.4B
2020$25.4B$9.1B$7.3B$12.31$9.9B

Latest SEC filings

What Amgen Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 5, 2026
    Quarterly report 10-Q · period to June 30, 2026
  2. August 4, 2026
    Quarterly results 8-K
  3. July 31, 2026
    Cybersecurity incident 8-K
  4. June 11, 2026
    Employee plan annual report 11-K
  5. June 11, 2026
    Employee plan annual report 11-K
  6. May 20, 2026
    Shareholder vote results 8-K
  7. May 19, 2026
    Executive or director change 8-K
  8. May 14, 2026
    Passive stake (5% or more) SCHEDULE 13G
  9. May 1, 2026
    Quarterly report 10-Q · period to March 31, 2026
  10. April 30, 2026
    Quarterly results 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 4, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about AMGN

What does Amgen Inc do?

Amgen discovers, develops, and manufactures biologic medicines based on recombinant DNA technology. It produces prescription drugs treating cancer, kidney disease, rheumatoid arthritis, and bone conditions, which it sells to hospitals, clinics, and pharmacies. Its shares trade on NASDAQ under the ticker AMGN.

Is Amgen Inc profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $8.7B on revenue of $38.1B, a net margin of 23.0%.

How much revenue does Amgen Inc make?

Over the twelve months to June 30, 2026 Amgen Inc reported revenue of $38.1B. That is 9.1% more than a year earlier.

When did Amgen Inc last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the new insider holdings from September 4, 2026.

Similar companies

GILD
Gilead Sciences, Inc.
BIIB
Biogen Inc.
BNTX
BioNTech SE
NBIX
Neurocrine Biosciences Inc
EXEL
Exelixis, Inc.
QGEN
Qiagen N.V.

Follow AMGN

Get an email when Amgen Inc files with the SEC: results, executive changes, material agreements and annual reports.

Follow AMGN: get an email when it files

Where the numbers come from

Financial figures are the values Amgen Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.